Unknown

Dataset Information

0

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.


ABSTRACT: Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. This trial (NSABP B-38; Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer) asked whether the incorporation of a fourth drug could improve outcomes relative to two standard regimens and provided a direct comparison of those two regimens.We randomly assigned 4,894 women with node-positive early-stage breast cancer to six cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC), four cycles of dose-dense (DD) doxorubicin and cyclophosphamide followed by four cycles of DD paclitaxel (P; DD AC?P), or DD AC?P with four cycles of gemcitabine (G) added to the DD paclitaxel (DD AC?PG). Primary granulocyte colony-stimulating factor support was required; erythropoiesis-stimulating agents (ESAs) were used at the investigator's discretion.There were no significant differences in 5-year disease-free survival (DFS) between DD AC?PG and DD AC?P (80.6% v 82.2%; HR, 1.07; P = .41), between DD AC?PG and TAC (80.6% v 80.1%; HR, 0.93; P = .39), in 5-year overall survival (OS) between DD AC?PG and DD AC?P (90.8% v 89.1%; HR, 0.85; P = .13), between DD AC?PG and TAC (90.8% v 89.6%; HR, 0.86; P = .17), or between DD AC?P versus TAC for DFS (HR, 0.87; P = .07) and OS (HR, 1.01; P = .96). Grade 3 to 4 toxicities for TAC, DD AC?P, and DD AC?PG, respectively, were febrile neutropenia (9%, 3%, 3%; P < .001), sensory neuropathy (< 1%, 7%, 6%; P < .001), and diarrhea (7%, 2%, 2%; P < .001). Exploratory analyses for ESAs showed no association with DFS events (HR, 1.02; P = .95).Adding G to DD AC?P did not improve outcomes. No significant differences in efficacy were identified between DD AC?P and TAC, although toxicity profiles differed.

SUBMITTER: Swain SM 

PROVIDER: S-EPMC3757290 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6712613 | BioStudies
2015-01-01 | S-EPMC4503103 | BioStudies
2018-01-01 | S-EPMC6252384 | BioStudies
2017-01-01 | S-EPMC5834079 | BioStudies
2020-01-01 | S-EPMC7577763 | BioStudies
2015-01-01 | S-EPMC4368615 | BioStudies
2019-09-13 | GSE137356 | GEO
2018-01-01 | S-EPMC5888953 | BioStudies
2019-01-01 | S-EPMC6473288 | BioStudies
2005-01-01 | S-EPMC2362097 | BioStudies